Overview

  • Product name

    Anti-MEK2 antibody [Y78] (HRP)
    See all MEK2 primary antibodies
  • Description

    Rabbit monoclonal [Y78] to MEK2 (HRP)
  • Host species

    Rabbit
  • Conjugation

    HRP
  • Tested applications

    Suitable for: WBmore details
  • Species reactivity

    Reacts with: Human
    Predicted to work with: Mouse
  • Immunogen

    Synthetic peptide. within Human MEK2 aa 1 to the C-terminus (N terminal). The exact sequence is proprietary.
    Database link: P36507

  • Positive control

    • WB: Jurkat whole cell lysate.
  • General notes

    Alternative versions available:
    Anti-MEK2 antibody [Y78] (ab32517) - Knockout validated

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

Properties

Applications

Our Abpromise guarantee covers the use of ab200607 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/7500. Detects a band of approximately 45 kDa (predicted molecular weight: 44 kDa).

Target

  • Function

    Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates the ERK1 and ERK2 MAP kinases.
  • Involvement in disease

    Defects in MAP2K2 are a cause of cardiofaciocutaneous syndrome (CFC syndrome) [MIM:115150]; also known as cardio-facio-cutaneous syndrome. CFC syndrome is characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. The inheritance of CFC syndrome is autosomal dominant.
  • Sequence similarities

    Belongs to the protein kinase superfamily. STE Ser/Thr protein kinase family. MAP kinase kinase subfamily.
    Contains 1 protein kinase domain.
  • Post-translational
    modifications

    MAPKK is itself dependent on Ser/Thr phosphorylation for activity catalyzed by MAP kinase kinase kinases (RAF or MEKK1).
    Acetylation of Ser-222 and Ser-226 by Yersinia yopJ prevents phosphorylation and activation, thus blocking the MAPK signaling pathway.
  • Information by UniProt
  • Database links

  • Alternative names

    • Cardiofaciocutaneous syndrome antibody
    • CFC syndrome antibody
    • CFC4 antibody
    • Dual specificity mitogen activated protein kinase kinase 2 antibody
    • Dual specificity mitogen-activated protein kinase kinase 2 antibody
    • ERK activator kinase 2 antibody
    • FLJ26075 antibody
    • MAP kinase kinase 2 antibody
    • map2k2 antibody
    • MAPK / ERK kinase 2 antibody
    • MAPK/ERK kinase 2 antibody
    • MAPKK 2 antibody
    • MAPKK2 antibody
    • MEK 2 antibody
    • MEK2 antibody
    • Microtubule associated protein kinase kinase 2 antibody
    • Mitogen activated protein kinase kinase 2 antibody
    • Mitogen activated protein kinase kinase 2 p45 antibody
    • MKK 2 antibody
    • MKK2 antibody
    • MP2K2_HUMAN antibody
    • OTTHUMP00000165826 antibody
    • OTTHUMP00000165827 antibody
    • PRKMK 2 antibody
    • PRKMK2 antibody
    see all

Images

  • All lanes : Anti-MEK2 antibody [Y78] (HRP) (ab200607) at 1/7500 dilution

    Lane 1 : Wild-type HAP1 whole cell lysate
    Lane 2 : MAP2K2 (MEK2) knockout HAP1 whole cell lysate

    Lysates/proteins at 20 µg per lane.

    Predicted band size: 44 kDa
    Observed band size: 44 kDa


    Exposure time: 30 seconds


    ab200607 was shown to specifically react with MEK2 in wild-type HAP1 cells as signal was lost in MAP2K2 (MEK2) knockout cells. Wild-type and MAP2K2 (MEK2) knockout samples were subjected to SDS-PAGE. Ab200607 and ab184095 (Mouse monoclonal [mAbcam 9484] to GAPDH - Loading Control (Alexa Fluor® 680) loading control) were incubated overnight at 4°C at 1/7500 dilution and 1/1000 dilution respectively. The loading control was imaged using the Licor Odyssey CLx prior to blots being developed with ECL technique.

  • Anti-MEK2 antibody [Y78] (HRP) (ab200607) at 1/7500 dilution + Jurkat (Human T cell lymphoblast-like cell line) Whole Cell Lysate at 10 µg

    Developed using the ECL technique.

    Performed under reducing conditions.

    Predicted band size: 44 kDa
    Observed band size: 45 kDa
    why is the actual band size different from the predicted?
    Additional bands at: 100 kDa. We are unsure as to the identity of these extra bands.


    Exposure time: 10 seconds


    This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 2% Bovine Serum Albumin before being incubated with ab200607 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.

References

ab200607 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab200607.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up